Hepatitis B status in hemodialysis patients

Guimarães, Maia Nogueira C.; Facincani, Tila; Santos, Suelen Silvana dos

doi:10.1590/s0004-2803.201700000-34

Cited by 12 publications

(10 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Brazil, prevalence of HBsAg of 0, 2.4, 7, 10, 34.1% were reported in hemodialysis center in Southeast, Central, Northeast, South and Midwest regions of Brazil [78][79][80][81][82]. HBsAg prevalence of 4.5, 25, 1.4% was found in hemodialysis patients in Peru, Venezuela, Cuba [59,67].…”

Section: Hepatitis B and C Prevalence In Patients With Chronic Kidneymentioning

confidence: 99%

Emergence of New Epidemiological Hepatitis B and C Profiles in High Risk Groups in Latin America

Villar¹,

Cruz²,

Portilho³

et al. 2018

Public Health - Emerging and Re-Emerging Issues

View full text Add to dashboard Cite

Latin America includes Mexico, the islands of the Caribbean and Central and South America, which possess a rich cultural and natural heritage. A narrative literature review was made to determine epidemiological hepatitis B and C profiles in high risk groups in Latin America, such as, drug users, hemophiliacs, and chronic kidney disease (CKD), human immunodeficiency virus (HIV) infected individuals. Using data from international databases that disseminate published quality studies. All studies with desired information regarding site and study population were included. It was observed that HBV prevalence diminished in several groups, probably due to implementation of HBV vaccination in various Latin America Countries (LACs). On the other hand, HCV prevalence is high among high risk groups compared to general population, but different values were observed in LAC, probably due to different access to education programs, assays evaluated, population size and type of recruitment. Due to chronicity of HBV and HCV, it is important to increase access to diagnosis, HBV vaccination and implementation of education programs to high risk groups to diminish burden of these infections.

show abstract

Section: Hepatitis B and C Prevalence In Patients With Chronic Kidneymentioning

confidence: 99%

Emergence of New Epidemiological Hepatitis B and C Profiles in High Risk Groups in Latin America

Villar¹,

Cruz²,

Portilho³

et al. 2018

Public Health - Emerging and Re-Emerging Issues

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Patients receiving hemodialysis (HD) are at an increased risk of hepatitis B infection for a variety of reasons including potential exposure due to improper disinfection of fomites (e.g., chair, equipment, dialysis machine), frequent diagnostic and therapeutic procedures, immune dysfunction, and reduced rates of vaccination response. [1][2][3] Hepatitis vaccination has a 95% to 100% response rate in the general population 4 compared to lower response rates reported in HD patients ranging from 55% to 88%. [5][6][7][8][9][10][11] Due to lower response rates in HD patients, the current recommendation is to administer a higher dose regimen of 40 μg given either as a 3-dose regimen (Recombivax-HB ® , Merck Frosst, Quebec, CA) or 4-dose regimen (Engerix B ® , GlaxoSmithKline, Ontario, CA) ( Table 1).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of a hepatitis B vaccination program at two tertiary hemodialysis centers

Kufta

Shalansky

Jastrzebski

et al. 2019

Hemodialysis International

View full text Add to dashboard Cite

Introduction: Hemodialysis (HD) patients are at increased risk of hepatitis B infection in comparison to the general population. Despite a more intensified hepatitis vaccination regimen, response rates in HD patients are typically low. The study was conducted to quantify response rate to a new hepatitis B vaccination protocol initiated in late 2015, determine risk factors affecting response rate, and assess adherence to protocol. Methods: This retrospective chart review evaluated all HD patients eligible for hepatitis B vaccination in two large dialysis clinics from initiation of the hepatitis B protocol to July 2017. Recombinant hepatitis vaccine (Recombivax® HB) 40 μg was administered in a 3‐dose regimen at months 0, 1, and 6 to patients with hepatitis B surface antibodies (anti‐HBs) <10 mIU/mL. A repeat series was given if anti‐HBs levels remained below 10 mIU/mL after the first series. A booster dose was given if anti‐HBs titers fell below 10 mIU/mL after initial response to a second series vaccination. Findings: Of 411 patients at the two HD centers, 142 patients received hepatitis B vaccination with a total of 168 vaccine courses given, series 1: n = 86, series 2: n = 60 and booster: n = 22. Response rates to vaccination were 61.4%, 58.3%, and 81.8%, respectively. In univariate analysis, adherence to protocol significantly affected response rate (P = 0.035). A multivariate analysis assessing response rates to series 1, 2 or booster confirmed that adherence was a significant risk factor (OR = 2.2; 95% CI 1.4–3.4; P = 0.0005). Discussion: This was the first study to examine adherence to regimen and identified adherence as an important predictor of vaccine response. Adherence is one of the few modifiable risk factors that can be optimized in an effort to improve response to hepatitis B vaccination.

show abstract

“…The reasons for high susceptibility to HBV among HD patients include invasive medical HD procedures, increased exposure to blood product transfusions, shared machines and equipment, and high prevalence of HBV among HD patients [7,10]. Prominent fibrosis, silent clinical presentations, and atypical serologic evolution are prevalent among dialysistreated HB patients [11]. A comprehensive systematic review of the HBV infection in Iranian HD patients showed that the HBV rate varied from 0 to 9.75% among these patients across different provinces [12].…”

Section: Introductionmentioning

confidence: 99%

An Investigation of the Immune Response to Hepatitis B Vaccination in Hemodialysis Patients at Dialysis Centers of Tehran (2016)

Hatami

Movafagh

Ramezankhani

2019

JOHE

View full text Add to dashboard Cite

Article Info Background: Hemodialysis (HD) patients are at an increased risk of acquiring the hepatitis B (HB) virus and having lower protective antibody levels as well as shorter durations of seroprotection. This study aims to determine the immune response of HB vaccination in HD patients referring to dialysis centers of the Tehran North Health Network. Materials and Methods: This descriptive study was conducted among all HD patients who referred to dialysis centers of the Tehran North Health Network in 2016. A total of 304 HD patients were included in this study using the census sampling method. Data were collected using a checklist, and the HBsAb level was evaluated by the ELISA test. The collected data were analyzed using analytical tests, including a chi-square test and the independent t-test. Results: The mean±sd values of the serum level of HBsAb were 90.44±97.51 and 105.73±100 IU/L in men and women, respectively. There was no association between the rate of the response to the HB vaccine and gender (P=0.82), age (P=0.13), weight (P=0.09), vaccine injection frequency (P=0.45), number of dialysis sessions/week (P=0.36), and blood type (P=0.97). In addition, there was no association between the response to the HB vaccine and the history of T2DM, HTN, renal transplantation, and cigarette smoking among the participants (P>0.05). Conclusion: One could conclude that the dialysis duration and the last injection of the HB vaccine would have a negative effect on the immune response rate among HD patients.

show abstract

Hepatitis B status in hemodialysis patients

Abstract: Despite the benefit of dosing of anti-HBc and anti-HBs before admission to dialysis, economic constraints have reduced the screening to only HBsAg. Since occult HBV infection has already been demonstrated in hemodialysis patients, the measure of anti-HBc should be encouraged.

Cited by 12 publications

References 12 publications

Emergence of New Epidemiological Hepatitis B and C Profiles in High Risk Groups in Latin America

Emergence of New Epidemiological Hepatitis B and C Profiles in High Risk Groups in Latin America

Effectiveness of a hepatitis B vaccination program at two tertiary hemodialysis centers

An Investigation of the Immune Response to Hepatitis B Vaccination in Hemodialysis Patients at Dialysis Centers of Tehran (2016)

Contact Info

Product

Resources

About